Abbott Laboratories (ABT)

Operating return on assets (Operating ROA)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Operating income (ttm) US$ in thousands 6,478,000 6,002,000 6,125,000 6,959,000 8,362,000 9,436,000 10,212,000 9,228,000 8,425,000 8,479,000 7,428,000 6,708,000 5,357,000 4,314,000 4,017,000 4,551,000 4,532,000 4,308,000 4,105,000 3,781,000
Total assets US$ in thousands 73,214,000 72,090,000 73,354,000 73,794,000 74,438,000 72,801,000 74,202,000 74,007,000 75,196,000 73,795,000 73,269,000 72,785,000 72,548,000 69,043,000 68,776,000 66,777,000 67,887,000 68,539,000 68,427,000 67,610,000
Operating ROA 8.85% 8.33% 8.35% 9.43% 11.23% 12.96% 13.76% 12.47% 11.20% 11.49% 10.14% 9.22% 7.38% 6.25% 5.84% 6.82% 6.68% 6.29% 6.00% 5.59%

December 31, 2023 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $6,478,000K ÷ $73,214,000K
= 8.85%

Abbott Laboratories' operating return on assets (ROA) has shown a downward trend over the past 8 quarters, declining from 12.47% in Q1 2022 to 8.85% in Q4 2023. The operating ROA peaked at 13.76% in Q2 2022 but has since decreased steadily.

This decrease in operating ROA could indicate that the company's operating income generated from its assets has been declining relative to its total assets. It is important to further investigate the reasons behind this trend, such as changes in operating efficiency, profitability, or asset management.

Investors and stakeholders may want to closely monitor Abbott Laboratories' operating ROA trend to understand the company's operational performance and effectiveness in utilizing its assets to generate profits.


Peer comparison

Dec 31, 2023